BIOLINERX
Careers | Contact Us
search

Press Releases
July 11, 2010
Company’s Board of Directors formally approved the process of registration with the U.S. SEC
June 21, 2010

BioLineRx signs $365 million North American out-licensing agreement for anti-psychotic drug BL-1020

Pursuant to agreement with Cypress Bioscience Inc., BioLineRx retains all rights for rest of world, enabling additional out-licensing opportunity for product at later stage

May 16, 2010
The Israel Laboratory Accreditation Authority (ISRAC) has granted BioLineRx's analytical laboratories Good Laboratory Practices (GLP)  accreditation as of  March 4, 2010 .
April 28, 2010
BioLineRx Ltd. is pleased to announce that Ikaria Holdings Inc. has made a $10 million milestone payment, according to the terms of the licensing agreement between the parties, following successful completion of the phase I/II clinical trial assessing the safety and feasibility of BL-1040 in patients who had experienced a significant acute myocardial infarction.
April 13, 2010
On Thursday April 15,  Yona Geffen, PhD, from BioLineRX will be presenting "A double-blind placebo control study evaluating the efficacy and safety of BL-1020 , a GABA enhanced antipsychotic for the treatment of schizophrenia" at  the SIRS Conference, "Cognition in Schizophrenia" Session.
March 7, 2010

BioLineRx Ltd. is pleased to announce that on March 4, 2010, it received the final assessment of the ISMB regarding the Phase I/II clinical trial for BL-1040, a medical device indicated for the treatment of patients who have experienced a heart attack.

January 17, 2010
We are pleased to report positive results from the 6-week extension trial.
October 18, 2009
BioLineRx’s Early Development Program provides funding for early stage research and development of innovative therapeutics.
September 24, 2009
Patients with schizophrenia suffer from significant cognitive dysfunction. This is reflected in difficulty of daily functioning, decreased ability to maintain a normal social relationships and impaired job performance.
September 14, 2009
BL-1020 meets primary and secondary efficacy endpoints from the phase 2b EAGLE trial
291-300  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next